Investigational New Drugs **11:** 343–345, 1993.

CONTENTS VOL. 11, 1993

Preclinical Studies

Chloroquinoxaline sulfonamide: A sulfanilamide antitumor agent entering clinical trials – J.S. Fisherman, B.L. Osborn, H.G. Chun, J. Plowman, A.C. Smith, M.C. Christian, D.S. Zaharko, R.H. Shoemaker 1

Cytotoxicity of crotoxin on murine erythroleukemia cells *in vitro* – R.E. Corin, L.J. Viskatis, J.C. Vidal, M.A. Etcheverry 11

Phase I Studies

A phase I clinical and pharmacokinetic study of the oral and the oral/intravenous administration of menogaril – G.R. Weiss, T.D. Brown, J.G. Kuhn, D.D. Von Hoff, R.H. Earhart, W.J. Adams, J.E. Brewer, J.D. Hosley, D.A. Kasunic 17

Phase I trial of dihydrolenperone in lung cancer patients: A novel compound with *in vitro* activity against lung cancer – B.E. Johnson, R. Parker, C.M. Tsai, J. Baltz, M.J. Miller, R. Shoemaker, R. Phelps, A. Bastian, J. Stocker, J. Phares, J.L. Mulshine, A.F. Gazdar, D.C. Ihde 29

Phase II Studies

Phase II study of alpha-interferon and 13-*cis*-retinoic acid in metastatic melanoma – K. Dhingra, N. Papadopoulos, S. Lippman, R. Lotan, S.S. Legha 39

Phase II study of trimetrexate in previously untreated patients with hepatocellular carcinoma: A Southwest Oncology Group study 8712 – W.H. Harvey, T.R. Fleming, P.J. Goodman, J.H. Harvey, S.E. Rivkin, J.S. MacDonald 45

Amonafide treatment of refractory esophageal cancer. A Southwest Oncology Group study – E. Poplin, T. Fleming, J.S. MacDonald, P. Eisenberg, R.I. Fisher, M.E. Conrad 47

A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer – D.G. Pfister, D. Bajorin, R.J. Motzer, H. Scher, C. Louison, L. Harrison, J. Shah, E. Strong, G. Bosl 53

Phase II trial of 13-*cis*-retinoic acid plus interferon-α in recurrent head and neck cancer – N. Voravud, S.M. Lippman, R.S. Weber, G.I. Rodriquez, D. Yee, I.W. Dimery, C.L. Earley, D.D. Von Hoff, W. Ki Hong 57

Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer – M. Moore, J. Maroun, F. Robert, R. Natale, J. Neidhart, B. Dallaire, R. Sisk, J. Gyves 61

Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma – J.A. Ajani, J.L. Abbruzzese, A.B. Markowitz, Y.Z. Patt, K. Daugherty 67

Phase II study of fazarabine (NSC 281272) in patients with metastatic colon cancer – N. Ben-Baruch, A.M. Denicoff, B.R. Goldspiel, J.A. O'Shaughnessy, K.H. Cowan 71

Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer – G.T. Budd, R.M. Bukowski, A. Lichtin, L. Bauer, P. Van Kirk, R. Ganapathi 75

Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer: A Southwest Oncology Group study – S.K. Williamson, J. Crowley, R.B. Livingston, G. Weiss 81

Phase II trial of gallium nitrate in previously treated patients with small cell lung cancer – J. Baselga, M.G. Kris, H.I. Scher, M. Phillips, R.T. Heelan 85

Phase II study of sulofenur (LY 186641). A novel antineoplastic agent in advanced non-small cell lung cancer – N.C. Munshi, D.E. Seitz, F. Fossella, S.M. Lippman, L.H. Einhorn 87

Mitogauzone, cisplatin, and vinblastine in advanced non-small cell lung cancer. A Southwest Oncology Group study – R. Chapman, J. Crowley, J.G. Lucas, B.L. Hom, R.B. Livingston, C.B. Vaughn, H.E. Hynes 91

New formulation intravenous melphalan in the treatment of patients with metastatic renal cancer – C.I. Falkson 93

Book Reviews

Antibodies as carriers of cytotoxicity. H.-H. SedLacek *et al.* (eds). Reviewed by J. Tami 95

Alkylphosphocholines: New drugs in cancer therapy. Progress in Experimental Tumor Research, Vol 34. H. Eibl *et al.* (eds). Reviewed by A.R. Hanauske 97

Announcement 99

Review

Is there a role for vindesine in the treatment of non-small cell lung cancer? – J.B. Sørensen, H.H. Hansen 103

Preclinical Studies

Cerebrospinal fluid pharmacokinetics and toxicology of intraventricular and intrathecal arabinosyl-5-azacytisine (fazarabine, NSC 281272) in the nonhuman primate – R.L. Heideman, C. McCully, F.M. Balis, D.G. Poplack 135

Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography – O. van Tellingen, A.V. Kuijpers, J.H. Beijnen, W.J. Nooijen, A. Bult 141

VRCTC-310 – A novel compound of purified animal toxins separates antitumor efficacy from neurotoxicity – R.A. Newman, J.C. Vidal, J.L. Viskatis, J. Johnson, M.A. Etcheverry 151

Chemotherapy of mammary carcinomas arising in ras transgenic mice – D.L. Dexter, M. Diamond, J. Creveling, S.-F. Chen 161

Phase I Studies

A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors – D.R. Adkins, R. Irvin, J. Kuhn, D.H. Boldt, G.D. Roodman, D. Salzman, C. Freytes, D.D. Von Hoff, C.F. LeMaistre 169

Phase I trial of 5-fluorouracil by 24-hour infusion weekly – N.B. Haas, J.B. Hines, G.R. Hudes, N. Johnston, R.F. Ozols, P.J. O'Dwyer 181

Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD) – S. Danhauser-Riedl, E. Hausmann, H.-D. Schick, R. Bender, H. Dietzfelbinger, J. Rastetter, A.-R. Hanauske 187

Phase II Studies

Mitoxantrone (dihydroxyanthracenedione) in acute leukemia: An evaluation of two treatment schedules by the Southwest Oncology Group – J.H. Saiki, W.J. Stuckey, J.W. Athens, B.L. Tranum, E. Van Slyck, D.D. Von Hoff 197

5-Azacytidine (NSC 102816) in refractory germ cell tumors: A phase II trial of the Eastern Cooperative Oncology Group – B.J. Roth, P. Elson, G.W. Sledge Jr., L.H. Einhorn, D.L. Trump 201

Phase II evaluation of the sulfonylurea LY186,641 in men with hormone independent metastatic prostate cancer – G. Wilding, G. Grindey, N. Munshi, D. Seitz, L. Einhorn 203

Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma: A Southwest Oncology Group study – M.E. Marshall, M.K. Wolf, E.D. Crawford, S. Taylor, B. Blumenstein, R. Flanigan, F.J. Meyers, H.E. Hynes, B. Barlogie, M. Eisenberger 207

Polyethylene glycol conjugated interleukin-2: Clinical and immunologic effects in patients with advanced renal cell carcinoma – R.M. Bukowski, J. Young, G. Goodman, F. Meyers, B.F. Issell, J.S. Sergi, D. McLain, G. Fyfe, J. Finke 211

Phase II trial of amonafide in advanced pancreas cancer: A Southwest Oncology Group study – C.G. Leichman, C. Tangen, J.S. Macdonald, T. Leimert, T.R. Fleming 219

Evaluation of amonafide in disseminated malignant melanoma: A Southwest Oncology Group study – M. Slavik, K.J. Kopecky, V. Sondak. J.B. Craig, M.K. Samson 223

Phase II trial of piroxantrone in patients with recurrent and metastatic squamous cell carcinoma of the head and neck: A Southwest Oncology Group trial – S.A. Taylor, J. Benedetti, D. Schuller, S.P. Richman, G. O. Broun, A. Hantel 227

Phase II trial of carbetimer in metastatic melanoma – D.W.Y. Quan Jr., M.S. Mitchell 231

Phase II study on DuP 937 (Teloxantrone) in colorectal carcinoma: A Canadian National Cancer Institute Clinical Trial Group study – J.A. Maroun, J. Skillings, R. MacCormick, M. Potvin, G. Wielgosz, J.R. Davidson, E. Eisenhauer 235

Announcement 239

Review

Methodological issues in antiemetic studies – M. Aapro 243

Preclinical Studies

Pharmacokinetics, cerebrospinal fluid penetration, and metabolism of piroxantrone in the Rhesus monkey – S.L. Berg, F.M. Balis, K.S. Godwin, D.G. Poplack 255

Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in mice – M.-C. Bissery, C.H. Nguyen, E. Bisagni, P. Vrignaud, F. Lavelle 263

Effects of diflubenzuron and clanfenur on mouse bone marrow cells – V.K. Jenkins, H.S. Juneja, K. Ives, S. Lee, R.R. Perry 279

Phase I Clinical Trials

Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies – J.H. Schiller, B. Storer, R. Arzoomanian, K. Tutsch, D. Albert, D. Spriggs 291

Phase I pharmacokinetic study of DUP-937, a new anthrapyrazole – K. Bélanger, J. Jolivet, J. Maroun, D. Stewart, A. Grillo-Lopez, L. Whitfield, N. Wainman, E. Eisenhauer 301

A phase I trial of fazarabine in refractory pediatric solid tumors. A Pediatric Oncology Group study – M.L. Bernstein, V.M. Whitehead, H. Grier, R. Dubowy, V. Land, S. Devine, S. Murphy, F. Kung 309

Phase I clinical and pharmacokinetic study of menogaril (7-con-0-methylnogarol) in previously treated patients with acute leukemia – C. Mazurek, J.P. Dutcher, E.L. Schwartz, S. Garl, L. Benson, P.H. Wiernik 313

Phase II Clinical Trials

Phase II trial of LY 186641 in advanced renal cancer – M. Mahjoubi, J. Kattan, M. Bonnay, H. Schmitt, J.-P. Droz 323

A phase II trial of piroxantrone in adenocarcinoma of the pancreas. A Southwest Oncology Group study – T.R. Jenkins, C. Tangen, J.S. Macdonald, G. Weiss, R. Chapman, A. Hantel 329

VM-26 in gastric cancer. A Southwest Oncology Group study – J.L. Berenberg, C. Tangen, J.S. Macdonald, B. Barlogie, L. Rogers Laufman 333

A phase II trial of gallium nitrate in advanced previously untreated colorectal cancer – V.A. Canfield, A.P. Lyss 335

Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas. A Southwest Oncology Group study – M.M. Zalupski, J. Benedetti, S.P. Balcerzak, L.F. Hutchins, R.J. Belt, A. Hantel, J. Wendall Goodwin 337

Contents Volume 11, 1993 343

Author Index 347